NeuroSense Therapeutics Ltd. (NASDAQ:NRSNW – Get Free Report) was the recipient of a large decline in short interest in the month of September. As of September 30th, there was short interest totaling 893 shares, a decline of 49.8% from the September 15th total of 1,779 shares. Based on an average trading volume of 2,775 shares, the short-interest ratio is presently 0.3 days.
NeuroSense Therapeutics Stock Performance
NRSNW traded up $0.00 during midday trading on Friday, reaching $0.01. The company had a trading volume of 10,030 shares, compared to its average volume of 2,602. The business has a 50-day moving average of $0.06 and a two-hundred day moving average of $0.11. NeuroSense Therapeutics has a 1 year low of $0.00 and a 1 year high of $0.54.
NeuroSense Therapeutics Company Profile
NeuroSense Therapeutics Ltd. is a clinical-stage biotechnology company developing treatments for neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and Alzheimer’s disease. The company focuses on therapies intended to address multiple biological mechanisms involved in disease progression, including neuroinflammation, mitochondrial dysfunction and RNA-processing abnormalities.
NeuroSense’s lead product candidate is PrimeC, an investigational oral fixed-dose combination of ciprofloxacin and celecoxib being developed primarily for ALS.
Further Reading
- Five stocks we like better than NeuroSense Therapeutics
- Bank of America Stock Sell-Off Looks Like a Buying Opportunity
- AST SpaceMobile Is Down 67%—Could SpaceX’s Mobile Push Deepen the Selloff?
- GlobalFoundries’ $21 Billion Deal Could Change the Economics of Chipmaking
- Fundamental and Technicals Signals Align for Costco: Is the Stock Finally Breaking Out?
Receive News & Ratings for NeuroSense Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroSense Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
